Dm in-depth

Overview of Diabetes Mellitus and Epidemiology

  • Etymology and Historical Context:

    • The term diabetes derives from the Greek word for "fountain" and the Latin word for "honey."

    • It describes the production of large volumes of glucose-rich urine in untreated patients. Historically, diagnosis was made by the sweet smell and taste of urine.

  • Pathophysiology Overview:

    • Primary disorder of carbohydrate metabolism, though insulin deficiency or resistance also severely disrupts protein and lipid metabolism.

    • Principal sign: Sustained hyperglycemia resulting from impaired cellular glucose uptake and increased hepatic glucose production.

    • Acute symptoms: Polyuria, polydipsia, ketonuria, and rapid weight loss.

    • Long-term vascular and neurological complications: Heart disease, renal failure, blindness, neuropathy, impotence, and stroke.

  • Epidemiology and Prevalence (CDC 2022 Report):

    • Diabetes is the most common endocrine disorder and the seventh leading cause of death by disease in the United States.

    • Approximately 37.3 million37.3\text{ million} Americans have diabetes, and nearly one-fourth (∼25%\thicksim 25\%) are undiagnosed.

    • An estimated 96 million96\text{ million} US adults (ages 18 years18\text{ years} and older) have prediabetes.

Etiology and Classification of Diabetes

  • Type 1 Diabetes (T1D):

    • Prevalence & Onset: Accounts for approximately 5%5\% of all diabetes cases. Usually develops during childhood or adolescence with an abrupt onset of symptoms, though it can manifest in adulthood.

    • Primary Defect: Autoimmune destruction of pancreatic β\beta cells in the Islets of Langerhans, which synthesize and release insulin. Insulin levels are reduced early in the disease and fall to zero over time.

    • Etiology: Triggered by an autoimmune process influenced by genetic, environmental, and infectious factors.

    • Clinical Profile: High risk for ketoacidosis; patients are typically thin/undernourished at diagnosis; family history is frequently negative.

    • Blood Glucose Stability: Fluctuates widely in response to infection, exercise, caloric intake, and insulin dose variations.

    • Management: Mandatory daily insulin replacement coordinated with strict dietary control.

  • Type 2 Diabetes (T2D):

    • Prevalence & Onset: Accounts for 90% to 95%90\% \text{ to } 95\% of all diagnosed cases. Typically begins in middle age and progresses gradually, though childhood onset has increased significantly.

    • Primary Defect: Combination of target tissue insulin resistance and impaired insulin secretion. Pancreatic β\beta cells retain the capacity to synthesize insulin, but release is delayed and peak output is subnormal.

    • Mechanism of Insulin Resistance: Target tissues (liver, skeletal muscle, adipose tissue) exhibit reduced insulin binding to receptors, reduced receptor numbers, and reduced receptor responsiveness. Over time, hyperglycemia causes β\beta-cell exhaustion, leading to declining insulin synthesis.

    • Etiology: Strong familial association; implicated genes include insulin receptor substrate-2 (IRS-2\text{IRS-2}), which mediates intracellular responses to insulin.

    • Clinical Profile: Low risk for ketoacidosis; patients are frequently obese at diagnosis; family history is frequently positive; blood glucose levels are generally more stable than in T1D.

    • Management: Oral antidiabetic agents, non-insulin injectables, and/or insulin, always combined with a reduced-calorie diet and structured exercise.

  • Comparative Summary of Diabetes Types (Table 48-1):

    • Age of Onset: T1D = usually childhood/adolescence; T2D = usually older than 40 years40\text{ years}.

    • Speed of Onset: T1D = abrupt; T2D = gradual.

    • Family History: T1D = frequently negative; T2D = frequently positive.

    • Primary Defect: T1D = loss of pancreatic β\beta cells; T2D = insulin resistance and inappropriate insulin secretion.

    • Insulin Levels: T1D = reduced early, absent later; T2D = low, normal, or high.

    • Ketoacidosis: T1D = common; T2D = uncommon.

  • Gestational Diabetes & Diabetes in Pregnancy:

    • Definition: Diabetes appearing during pregnancy that subsides rapidly after delivery.

    • Pathophysiologic Factors in Pregnancy:

    • Placental hormones antagonize insulin actions.

    • Cortisol production increases threefold (3×3\times) during pregnancy, promoting hyperglycemia.

    • Maternal hyperglycemia causes glucose to pass freely across the placenta, stimulating fetal hyperinsulinism, which leads to fetal macrosomia and adverse birth outcomes.

    • Management: Requires diligent glucose control. Insulin is the preferred agent; metformin is used in select cases.

Diagnostic Criteria and Prediabetes

  • Criteria for the Diagnosis of Diabetes (Table 48-2):

    • Fasting Plasma Glucose (FPG): ≥126 mg/dL\ge 126\text{ mg/dL} (fasting defined as no caloric intake for at least 8 hours8\text{ hours}).

    • Random Plasma Glucose: ≥200 mg/dL\ge 200\text{ mg/dL} plus classic symptoms of diabetes (polyuria, polydipsia, unexplained weight loss).

    • Oral Glucose Tolerance Test (OGTT): 2-hour plasma glucose ≥200 mg/dL\ge 200\text{ mg/dL} following ingestion of 75 g75\text{ g} anhydrous glucose dissolved in water.

    • Hemoglobin A1c: ≥6.5%\ge 6.5\% or higher.

  • Prediabetes Guidelines:

    • Diagnostic Parameters: Impaired Fasting Glucose (FPG 100 to 125 mg/dL\text{FPG } 100\text{ to } 125\text{ mg/dL}) OR Impaired Glucose Tolerance (2-hour OGTT 140 to 199 mg/dL\text{OGTT } 140\text{ to } 199\text{ mg/dL}).

    • Associated Risks: Increased risk for developing T2D and cardiovascular disease (CVD), but NOT microvascular complications (retinopathy, nephropathy, neuropathy).

    • Interventions: Moderate exercise plus weight loss (5% to 7%5\% \text{ to } 7\% of body weight) reduces T2D progression risk by 58%58\% overall (and 71%71\% in adults age ≥60 years\ge 60\text{ years}).

Management Overview and Glycemic Targets

  • Comprehensive Management Goals:

    • Achieve safe glycemic control while minimizing hypoglycemia.

    • Manage comorbidities: Hypertension (2023 ADA target ≤130/80 mmHg\le 130/80\text{ mmHg} using ACE inhibitors like lisinopril or ARBs like losartan) and Dyslipidemia (using HMG-CoA reductase inhibitors/statins to reduce CV events).

  • General Glycemic Treatment Targets for Nonpregnant Adults (Table 48-3):

    • Hemoglobin A1c: <7.0%< 7.0\% (Individualized target <8.0%< 8.0\% for patients with severe hypoglycemia history, limited life expectancy, or advanced complications).

    • Premeal (Preprandial) Plasma Glucose: 80 to 130 mg/dL80\text{ to } 130\text{ mg/dL}.

    • Peak Postprandial Plasma Glucose (1--2 hours post-meal): <180 mg/dL< 180\text{ mg/dL}.

  • Hemoglobin A1c and Estimated Average Glucose (eAG) Conversion (Table 48-4):

    • Conversion Formula: eAG=(28.7×A1c)−46.7\text{eAG} = (28.7 \times \text{A1c}) - 46.7

    • A1c 6.0%=126 mg/dL\text{A1c } 6.0\% = 126\text{ mg/dL}

    • A1c 7.0%=154 mg/dL\text{A1c } 7.0\% = 154\text{ mg/dL}

    • A1c 8.0%=183 mg/dL\text{A1c } 8.0\% = 183\text{ mg/dL}

    • A1c 9.0%=212 mg/dL\text{A1c } 9.0\% = 212\text{ mg/dL}

    • A1c 10.0%=240 mg/dL\text{A1c } 10.0\% = 240\text{ mg/dL}

    • A1c 11.0%=269 mg/dL\text{A1c } 11.0\% = 269\text{ mg/dL}

    • A1c 12.0%=298 mg/dL\text{A1c } 12.0\% = 298\text{ mg/dL}

  • Stepwise Management Approach in Type 2 Diabetes:

    • Step 1: Lifestyle modifications plus Metformin monotherapy at diagnosis.

    • Step 2: Lifestyle modifications + Metformin + a second high-efficacy drug (e.g., GLP-1 RA or SGLT-2 inhibitor). Consider basal insulin if target is unmet.

    • Step 3: Progress to a three-drug combination based on patient risk factors, social determinants, cost, and preferences.

    • Initial Combination Therapy Exceptions:

    • If A1c≥9.0%\text{A1c} \ge 9.0\% at diagnosis: Consider dual therapy immediately (Step 2).

    • If A1c≥10.0%\text{A1c} \ge 10.0\%, FPG≥300 mg/dL\text{FPG} \ge 300\text{ mg/dL}, or patient is markedly symptomatic: Consider immediate combination injectable therapy.

Insulin Physiology, Actions, and Complications

  • Endogenous Physiology:

    • Synthesized in pancreatic β\beta cells in the Islets of Langerhans.

    • Primary release stimulus: Elevation in blood glucose (eating a carbohydrate-rich meal).

    • Additional release triggers: Amino acids, fatty acids, ketone bodies, and incretins (GLP-1).

    • Autonomic Regulation: β2\beta_2-adrenergic receptor activation promotes insulin secretion; α\alpha-adrenergic receptor activation suppresses secretion.

  • Metabolic Actions of Insulin (Table 48-5):

    • Anabolic Mode:

    • Carbohydrates: Stimulates glucose uptake in muscle/adipose tissue; stimulates glucose oxidation in muscle; stimulates glycogen synthesis and storage in muscle/liver. Inhibits glycogenolysis and gluconeogenesis.

    • Amino Acids & Proteins: Stimulates amino acid uptake and protein synthesis in muscle; inhibits amino acid release.

    • Lipids: Stimulates triglyceride synthesis in adipose tissue; inhibits free fatty acid (FFA) and glycerol release; inhibits FFA oxidation to ketoacids in the liver.

    • Catabolic Mode (Insulin Deficiency):

    • Glycogen is broken down to glucose (glycogenolysis); gluconeogenesis is accelerated using amino acids and glycerol; proteins are degraded; fats are converted to FFAs and glycerol.

  • Complications of Insulin Therapy:

    • Hypoglycemia (Blood Glucose <70 mg/dL< 70\text{ mg/dL}):

    • Causes: Insulin overdose, decreased food intake, vomiting/diarrhea, excessive alcohol consumption, intense physical activity.

    • Sympathetic Symptoms (Rapid Decline): Tachycardia, palpitations, sweating, nervousness.

    • CNS Symptoms (Gradual Decline): Headache, confusion, drowsiness, fatigue; progresses to convulsions, coma, and death.

    • Treatment: Conscious: 15 to 20 g15\text{ to } 20\text{ g} fast-acting oral carbohydrates (glucose tablets, orange juice, sugar cubes, honey, non-diet soda). Unconscious/Gag Reflex Suppressed: IV dextrose (D50W\text{D}_{50}\text{W}) or parenteral glucagon.

    • Hypoglycemia Unawareness: Lack of sympathetic warning signs due to recurrent hypoglycemia; managed by temporarily loosening glycemic targets for several weeks.

    • Hypokalemia: Insulin stimulates Na+/K+\text{Na}^+/\text{K}^+-ATPase, pumping potassium into cells. Excessive insulin causes severe hypokalemia, resulting in cardiac dysrhythmias and reduced contractility.

    • Lipohypertrophy: Accumulation of subcutaneous fat at injection sites due to localized insulin-stimulated lipid synthesis. Prevented by rotating injection sites.

  • Drug Interactions with Insulin:

    • Hypoglycemic Agents: Sulfonylureas, glinides, and alcohol intensify insulin-induced hypoglycemia.

    • Hyperglycemic Agents: Thiazide diuretics, glucocorticoids, sympathomimetics, and antipsychotics raise blood glucose and counteract insulin.

    • β\beta-Adrenergic Blockers: Mask sympathetic warning signs of hypoglycemia (tachycardia, palpitations) and impair glycogenolysis.

Insulin Preparations and Pharmacokinetics

Time-Effect Relationship for Different Types of Insulin
  • Short Duration: Rapid Acting:

    • Insulin Lispro (Humalog): Onset = 15 to 30 min15\text{ to } 30\text{ min}; Peak = 0.5 to 2.5 h0.5\text{ to } 2.5\text{ h}; Duration = 3 to 6 h3\text{ to } 6\text{ h}. Strengths: U-100, U-200. SubQ injection within 15 min15\text{ min} before or immediately after meals; SubQ continuous infusion pump; IV (rare). Rx.

    • Insulin Aspart (NovoLog): Onset = 10 to 20 min10\text{ to } 20\text{ min}; Peak = 1 to 3 h1\text{ to } 3\text{ h}; Duration = 3 to 5 h3\text{ to } 5\text{ h}. Strength: U-100. SubQ injection 5 to 10 min5\text{ to } 10\text{ min} before meals; SubQ pump; IV (rare). Rx.

    • Insulin Glulisine (Apidra): Onset = 10 to 15 min10\text{ to } 15\text{ min}; Peak = 1 to 1.5 h1\text{ to } 1.5\text{ h}; Duration = 3 to 5 h3\text{ to } 5\text{ h}. Strength: U-100. SubQ injection within 15 min15\text{ min} before or 20 min20\text{ min} after meals; SubQ pump; IV (rare). Rx.

    • Inhaled Human Insulin (Afrezza): Mealtime rapid-acting dry powder inhaler. Cartridge strengths: 44, 88, and 12 units12\text{ units}. Rx.

  • Short Duration: Short Acting:

    • Regular Insulin (Humulin R, Novolin R):

    • Onset = 30 to 60 min30\text{ to } 60\text{ min}; Peak = 1 to 5 h1\text{ to } 5\text{ h}; Duration = 6 to 10 h6\text{ to } 10\text{ h}. SubQ injection 30 min30\text{ min} before meals, SubQ pump, IV infusion, IM (rare).

    • Strengths: U-100 (OTC) and U-500 (500 units/mL500\text{ units/mL}, Rx). U-500 is reserved for extreme insulin resistance (>200 units/day> 200\text{ units/day}). NEVER administer U-500 IV; always use dedicated U-500 syringes.

  • Intermediate Duration:

    • Neutral Protamine Hagedorn (NPH) Insulin Suspension (Humulin N, Novolin N):

    • Conjugated with protamine (foreign protein; risk of allergic reactions).

    • Onset = 60 to 120 min60\text{ to } 120\text{ min}; Peak = 6 to 14 h6\text{ to } 14\text{ h}; Duration = 16 to 24 h16\text{ to } 24\text{ h}. SubQ injection twice daily. Cloudy suspension (agitate gently prior to drawing). Only intermediate/long-acting insulin suitable for mixing with short-acting insulins. OTC.

  • Long Duration:

    • Insulin Glargine U-100 (Lantus, Basaglar, Semglee): Onset = 70 min70\text{ min}; Peak = None (peakless steady state); Duration = 18 to 24 h18\text{ to } 24\text{ h}. SubQ once or twice daily at the same time every day. Forms SubQ microprecipitates that slowly dissolve. Rx.

    • Insulin Detemir (Levemir): Onset = 60 to 120 min60\text{ to } 120\text{ min}; Peak = 12 to 24 h12\text{ to } 24\text{ h}; Duration = dose-dependent (0.2 units/kg=12 h0.2\text{ units/kg} = 12\text{ h}; 0.4 units/kg=20 to 24 h0.4\text{ units/kg} = 20\text{ to } 24\text{ h}). Being discontinued after December 2024. Rx.

  • Ultra-Long Duration:

    • Insulin Glargine U-300 (Toujeo): Onset = 360 min360\text{ min}; Peak = None; Duration = >24 h> 24\text{ h}. SubQ once daily. Rx.

    • Insulin Degludec (Tresiba): Onset = 30 to 90 min30\text{ to } 90\text{ min}; Peak = None; Duration = >24 h> 24\text{ h}. Strengths: U-100, U-200. SubQ once daily. Rx.

  • Premixed Insulin Combinations (Table 48-8):

    • 70%70\% NPH / 30%30\% Regular (Humulin 70/30, Novolin 70/30): OTC.

    • 50%50\% NPH / 50%50\% Regular (Humulin 50/50): OTC.

    • 70%70\% Insulin aspart protamine / 30%30\% Insulin aspart (NovoLog Mix 70/30): Rx.

    • 75%75\% Insulin lispro protamine / 25%25\% Insulin lispro (Humalog Mix 75/25): Rx.

    • 50%50\% Insulin lispro protamine / 50%50\% Insulin lispro (Humalog Mix 50/50): Rx.

  • Rules for Mixing Insulins:

    • Mix only compatible insulins. Only NPH is approved for mixing with short-acting insulins (regular, lispro, aspart, glulisine).

    • Always draw the short-acting (clear) insulin into the syringe FIRST to prevent contaminating the short-acting vial with NPH (cloudy).

  • Dosing Regimens:

    • Total daily dosage: 0.1 to >2.5 units/kg/day0.1\text{ to }>2.5\text{ units/kg/day}. T1D initial = 0.5 to 0.6 units/kg/day0.5\text{ to } 0.6\text{ units/kg/day}; T2D initial = 0.2 to 0.6 units/kg/day0.2\text{ to } 0.6\text{ units/kg/day}.

    • Regimens: Twice-daily premixed vs. Intensive basal-bolus strategy (basal insulin once daily + rapid-acting insulin before each meal).

    • Insulin requirements increase with: Infection, stress, obesity, adolescent growth spurt, pregnancy (2nd/3rd trimesters).

    • Insulin requirements decrease with: Exercise, 1st trimester of pregnancy.

Examples of Insulin Dosing Schedules

Oral Antidiabetic Medications

  • 1. Biguanides: Metformin (Glucophage, Glucophage XR, Fortamet, Glumetza, Riomet):

    • Mechanism of Action: Inhibits hepatic glucose production; reduces intestinal glucose absorption; sensitizes insulin receptors in target tissues (skeletal muscle and fat) to increase glucose uptake. Does NOT stimulate pancreatic insulin release (no risk of hypoglycemia when used alone).

    • Pharmacokinetics: Slowly absorbed in small intestine. NOT metabolized by the liver; excreted UNCHANGED by the kidneys. Half-life = 4 to 9 hours4\text{ to } 9\text{ hours}. Accumulates in renal impairment.

    • Therapeutic Uses: First-line therapy for T2D; prevention of T2D in high-risk patients; gestational diabetes; Polycystic Ovary Syndrome (PCOS - off-label, improves insulin sensitivity, lowers androgen levels, restores ovulation).

    • Adverse Effects: GI disturbances (decreased appetite, nausea, diarrhea; causes discontinuation in 3% to 5%3\%\text{ to } 5\%; minimize by titrating slowly and taking with meals); Decreased Vitamin B12\text{B}_{12} and folic acid absorption; Weight neutral or modest weight loss.

    • BLACK BOX WARNING / Lactic Acidosis: Severe, potentially fatal (50%50\% mortality) metabolic acidosis caused by metformin accumulation. Metformin inhibits mitochondrial oxidation of lactic acid. Extremely rare (3 cases per 100,000 patient-years3\text{ cases per } 100{,}000\text{ patient-years}) with normal renal function. CONTRAINDICATED in renal impairment, liver disease, severe infection, alcoholism, shock/hypoxia. Early signs: hyperventilation, myalgia, malaise, unusual somnolence. Treatment: drug withdrawal, hemodialysis.

    • Drug Interactions: Alcohol (potentiates lactic acidosis); Cimetidine (increases lactic acidosis risk); Iodinated Radiocontrast Media (causes acute renal failure; withhold metformin 1 to 2 days1\text{ to } 2\text{ days} prior to contrast procedures, resume 48 hours48\text{ hours} post-procedure if renal function is normal).

    • Dosing: Immediate Release (IR) starting 500 to 850 mg500\text{ to } 850\text{ mg} daily or 500 mg500\text{ mg} BID (max 2.55 g/day2.55\text{ g/day}); Extended Release (ER) starting 500 mg to 1 g500\text{ mg to } 1\text{ g} daily (max 2.0 g/day2.0\text{ g/day}).

  • 2. Second-Generation Sulfonylureas: Glipizide (Glucotrol), Glyburide (DiaBeta, Glynase), Glimepiride (Amaryl):

    • Mechanism of Action: Stimulates insulin release from pancreatic β\beta cells by blocking ATP-sensitive K+\text{K}^+ channels →\rightarrow membrane depolarization →\rightarrow Ca2+\text{Ca}^{2+} influx →\rightarrow insulin exocytosis.

    • Adverse Effects: Hypoglycemia (doses lower blood glucose regardless of baseline levels; severe risk in renal/hepatic impairment), Weight gain.

    • Drug Interactions: Alcohol (disulfiram-like reaction: flushing, palpitations, nausea; potentiates hypoglycemia); NSAIDs, sulfonamide antibiotics, cimetidine (intensify hypoglycemia); β\beta-blockers (suppress insulin release, mask hypoglycemic tachycardia).

    • Dosing: Glipizide IR 2.5 to 5 mg/day2.5\text{ to } 5\text{ mg/day} (max 40 mg40\text{ mg}); Glipizide ER 2.5 to 5 mg/day2.5\text{ to } 5\text{ mg/day} (max 20 mg20\text{ mg}); Glyburide nonmicronized 1.25 to 5 mg/day1.25\text{ to } 5\text{ mg/day} (max 20 mg20\text{ mg}), micronized 0.75 to 3 mg/day0.75\text{ to } 3\text{ mg/day} (max 12 mg12\text{ mg}); Glimepiride 1 to 2 mg/day1\text{ to } 2\text{ mg/day} (max 8 mg8\text{ mg}). Hold if patient is NPO.

  • 3. Meglitinides (Glinides): Repaglinide (Prandin), Nateglinide (Starlix):

    • Mechanism of Action: Same as sulfonylureas (blocks ATP-sensitive K+\text{K}^+ channels on β\beta cells).

    • Pharmacokinetics: Rapid onset, short duration. Taken within 30 minutes30\text{ minutes} before meals. Nateglinide duration = 2 hours2\text{ hours} (renally excreted); Repaglinide duration = 4 hours4\text{ hours} (≤10%\le 10\% renally excreted, safer in renal impairment).

    • Adverse Effects: Hypoglycemia, Weight gain. Skip dose if meal is skipped.

    • Drug Interaction: Gemfibrozil + Repaglinide: Gemfibrozil inhibits CYP2C8, dramatically increasing repaglinide levels and causing severe hypoglycemia (combination contraindicated).

  • 4. Thiazolidinediones (TZDs / Glitazones): Pioglitazone (Actos):

    • Mechanism of Action: Activates PPAR-γ\gamma (peroxisome proliferator-activated receptor gamma) in cell nucleus →\rightarrow turns on insulin-responsive genes →\rightarrow decreases insulin resistance, increases glucose uptake in muscle/fat, decreases hepatic glucose output. Requires presence of insulin.

    • BLACK BOX WARNING / Heart Failure: Renal fluid retention. Contraindicated in NYHA Class III and Class IV Heart Failure.

    • Adverse Effects: Upper respiratory tract infection, headache, myalgia, sinusitis; Bladder Cancer risk (long-term high dose; avoid in active/history of bladder cancer); Fractures in cisgender women (foot, hand, upper arm); Hepatotoxicity (monitor ALT at baseline and q3-6mo; stop if ALT >3×ULN> 3\times \text{ULN} or jaundice); Risk of ovulation/unintended pregnancy in anovulatory premenopausal women.

    • Drug Interactions: Insulin (increases fluid retention/HF risk); CYP2C8 inhibitors (gemfibrozil) increase levels; CYP2C8 inducers (rifampin) decrease levels.

  • 5. α\alpha-Glucosidase Inhibitors: Acarbose (Precose), Miglitol (Glyset):

    • Mechanism of Action: Reversibly inhibits α\alpha-glucosidase at the intestinal brush border →\rightarrow delays digestion and absorption of complex carbohydrates and oligosaccharides →\rightarrow reduces postprandial blood glucose spike.

    • Adverse Effects: GI distress (flatulence, abdominal cramps, distension, borborygmi, diarrhea due to bacterial fermentation of unabsorbed carbs in colon), Decreased iron absorption (anemia).

    • Hypoglycemia Treatment Rule: Does not cause hypoglycemia alone. If combined with insulin/sulfonylurea and hypoglycemia occurs, MUST treat with pure glucose (dextrose), NOT sucrose (table sugar), because acarbose inhibits sucrose hydrolysis.

    • Hepatotoxicity: Long-term high-dose acarbose can elevate liver transaminases (monitor q3mo for 1st year).

  • 6. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Gliptins): Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), Alogliptin (Nesina):

    • Mechanism of Action: Inhibits DPP-4 enzyme →\rightarrow prevents degradation of incretin hormones (GLP-1, GIP) →\rightarrow increases glucose-dependent insulin secretion, suppresses postprandial glucagon release, decreases hepatic glucose output.

    • Adverse Effects: Generally well tolerated (nasopharyngitis, headache, URI). Low risk of hypoglycemia alone. Rare: Acute pancreatitis (severe, persistent abdominal pain; stop drug immediately), severe hypersensitivity (anaphylaxis, angioedema, Stevens-Johnson syndrome), heart failure risk (saxagliptin, alogliptin).

  • 7. Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Steglatro), Bexagliflozin (Brenzavvy):

    • Mechanism of Action: Inhibits SGLT-2 in proximal renal tubules →\rightarrow blocks reabsorption of filtered glucose →\rightarrow increases urinary glucose excretion (glucosuria) →\rightarrow lowers blood glucose and promotes weight loss via caloric loss in urine.

    • Adverse Effects: Female genital mycotic infections, UTIs (urosepsis, pyelonephritis), postural hypotension/dizziness (due to osmotic diuresis; exacerbated by diuretics), euglycemic DKA (rare in T2D), Fournier's gangrene (necrotizing fasciitis of perineum), lower limb amputation risk (canagliflozin).

    • Drug Interactions: UGT inducers (rifampin, phenytoin, phenobarbital) decrease canagliflozin levels; diuretics increase dehydration/hypotension.

  • 8. Other Oral Antidiabetic Agents:

    • Colesevelam (Welchol): Bile acid sequestrant; lowers cholesterol and lowers blood glucose in T2D.

    • Bromocriptine (Cycloset): Dopamine agonist; acts in CNS to adjust metabolic control; reduces A1c by ∼0.5%\thicksim 0.5\%.

Non-Insulin Injectable Antidiabetic Medications

  • 1. GLP-1 Receptor Agonists (Incretin Mimetics):

    • Agents & Dosing:

    • Exenatide IR (Byetta): SubQ injection BID within 60 min60\text{ min} before morning and evening meals (5 to 10 mcg5\text{ to } 10\text{ mcg}).

    • Exenatide ER (Bydureon): SubQ injection once weekly (2 mg2\text{ mg}).

    • Liraglutide (Victoza): SubQ once daily (0.6 mg0.6\text{ mg} titrating to 1.2–1.8 mg1.2\text{--}1.8\text{ mg}). Saxenda brand used for obesity (3.0 mg3.0\text{ mg}).

    • Dulaglutide (Trulicity): SubQ once weekly (0.75 to 4.5 mg0.75\text{ to } 4.5\text{ mg}).

    • Semaglutide (Ozempic): SubQ once weekly (0.25 to 2.0 mg0.25\text{ to } 2.0\text{ mg}). Rybelsus is oral daily formulation (3 to 14 mg3\text{ to } 14\text{ mg}). Wegovy brand used for obesity.

    • Mechanism of Action: Synthetic analogs that activate GLP-1 receptors →\rightarrow slow gastric emptying, stimulate glucose-dependent insulin release, suppress postprandial glucagon release, reduce appetite.

    • Adverse Effects: GI distress (nausea, vomiting, diarrhea), hypoglycemia (when combined with sulfonylureas), acute pancreatitis (severe abdominal pain; discontinue), renal impairment secondary to dehydration/N/V/D.

    • BLACK BOX WARNING (Liraglutide, Dulaglutide, Semaglutide, Exenatide ER): Risk of thyroid C-cell tumors / Medullary Thyroid Carcinoma (MTC). Contraindicated in personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

  • 2. Dual GIP and GLP-1 Receptor Agonist:

    • Tirzepatide (Mounjaro for T2D; Zepbound for obesity):

    • Mechanism of Action: Dual agonist at both GIP and GLP-1 receptors →\rightarrow enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, markedly increases satiety →\rightarrow profound weight loss (25 to 47 lbs25\text{ to } 47\text{ lbs}).

    • Dosing: SubQ once weekly (2.5 mg2.5\text{ mg} starting, titrate by 2.5 mg2.5\text{ mg} q4wk up to max 15 mg15\text{ mg}).

    • Adverse Effects: GI effects (N/V/D, constipation, abdominal pain), pancreatitis, acute kidney injury.

    • Interactions: May decrease effectiveness of oral contraceptives (advise alternative birth control method).

  • 3. Amylin Mimetics:

    • Pramlintide (Symlin):

    • Mechanism of Action: Synthetic analog of amylin (co-secreted with insulin by β\beta cells) →\rightarrow delays gastric emptying, suppresses glucagon secretion, increases satiety.

    • Indication: Adjunct to mealtime insulin in T1D and T2D.

    • BLACK BOX WARNING / Hypoglycemia: Severe, insulin-induced hypoglycemia when combined with mealtime insulin, especially in T1D (occurs within 3 hours3\text{ hours} of dosing). Reduce mealtime insulin dose by 50%50\% initially upon starting pramlintide. Contraindicated in hypoglycemia unawareness, poor adherence, or recurrent hypoglycemia.

    • Interactions: Delays oral drug absorption due to slowed gastric emptying (take oral meds 1 hour1\text{ hour} before or 2 hours2\text{ hours} after pramlintide). Avoid with drugs that slow GI motility (antimuscarinics, opioids) or slow nutrient absorption (acarbose).

  • 4. Combination Injectable Products:

    • Soliqua 100/33: Fixed-dose combination of Insulin glargine + Lixisenatide (SubQ once daily).

    • Xultophy 100/3.6: Fixed-dose combination of Insulin degludec + Liraglutide (SubQ once daily).

Acute Complications: DKA, HHS, and Severe Hypoglycemia

Pathogenesis of Diabetic Ketoacidosis
  • Comparison of DKA and HHS (Table 48-21):

    • Diabetic Ketoacidosis (DKA):

    • Patient Population: Mainly Type 1 Diabetes.

    • Onset: Rapid (hours to days).

    • Blood Glucose Level: >250 mg/dL> 250\text{ mg/dL}.

    • Arterial Blood pH: ≤7.30\le 7.30.

    • Plasma Osmolality: ≤320 mOsm/kg\le 320\text{ mOsm/kg}.

    • Ketones: Large increase in blood and urine ketones.

    • Odor: Urine smells like rotten apples; breath smells sweet/fruity or like acetone (nail polish remover).

    • Pathogenesis: Severe insulin deficiency →\rightarrow uncontrolled lipolysis →\rightarrow FFA accumulation →\rightarrow hepatic oxidation of FFAs into ketoacids (β\beta-hydroxybutyric acid, acetoacetic acid) →\rightarrow metabolic acidosis + osmotic diuresis/dehydration →\rightarrow hemoconcentration, shock, coma, death.

    • Treatment: IV fluids and electrolytes (normalize Na+\text{Na}^+ and K+\text{K}^+ balance), followed by IV regular insulin infusion. Reduce blood glucose slowly at a rate of ∼50 mg/dL/h\thicksim 50\text{ mg/dL/h}.

    • Hyperosmolar Hyperglycemic State (HHS):

    • Patient Population: Mainly Type 2 Diabetes.

    • Onset: Gradual (evolves over weeks to months).

    • Blood Glucose Level: >600 mg/dL> 600\text{ mg/dL}.

    • Arterial Blood pH: >7.30> 7.30.

    • Plasma Osmolality: >320 mOsm/kg> 320\text{ mOsm/kg}.

    • Ketones: Little or no change (nonketotic).

    • Odor: Normal urine and breath odor.

    • Pathogenesis: Insulin deficiency allows extreme hyperglycemia and severe osmotic diuresis →\rightarrow profound dehydration, hemoconcentration, increased hematocrit, sluggish blood flow →\rightarrow seizures, coma, death.

    • Treatment: IV fluids, electrolytes, and IV regular insulin infusion.

  • Glucagon for Severe Hypoglycemia:

    • Source & Physiology: Polypeptide hormone produced by α\alpha cells in pancreatic Islets of Langerhans. Acts opposite to insulin by promoting glycogenolysis, inhibiting glycogen synthesis, and stimulating gluconeogenesis.

    • Indication: Treatment of severe hypoglycemia in ambulatory/home settings when IV glucose is unavailable.

    • Dosing & Administration: SubQ, IM, or IV injection (0.5 to 1.0 mg0.5\text{ to } 1.0\text{ mg} reconstituted powder); Intranasal formulation (Baqsimi); Ready-to-inject pen (Gvoke).

    • Clinical Considerations: Restores consciousness within ∼20 minutes\thicksim 20\text{ minutes}. Once conscious, administer oral carbohydrates immediately to prevent recurrent hypoglycemia and replenish liver glycogen stores. Ineffective in starved patients (depleted hepatic glycogen).